New Biotechnology research report from GBI Research is now available from Fast Market Research

Boston, MA -- (SBWire) -- 07/26/2012 --GBI Research, the leading business intelligence provider, has released its latest research on, "Biobetters in Key Markets - Opportunities for Biotechnology Companies to Sustain Innovation with Low Risk and High Value Offerings", which provides insights into the impact of biobetter therapies on the top selling biologic therapeutics, the regulatory procedure surrounding entry in the biobetters market and including recent technological advances that have driven advancement in the market. The report provides an in-depth analysis of top selling biobetter products covering top selling protein classes, erythropoietin's, granulocyte-colony stimulating factors (G-CSF), interferon-a, interferon-beta, insulin and insulin analogs, monoclonal antibodies (mAbs) and tumor Necrosis Factor-a (TNF-a). The report also includes insights into the biobetter therapeutics R&D pipeline. It analyzes the competitive landscape, including Mergers and Acquisitions (M&As), and licensing and co-development deals.

View Full Report Details and Table of Contents

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research found that on average biobetter launches generate more revenues than their corresponding originator therapies. In some scenarios this extended to, the launch of a biobetter therapy substituting the sales from an existing originator product or biobetter therapy.

Scope

- Data and analysis on the impact of biobetter therapeutics on the major top selling biologics erythropoietin's, granulocyte-colony stimulating factors (G-CSF), interferon-a, interferon-beta, insulin and insulin analogs, human growth hormone and monoclonal and mAbs.
- Pipeline analysis of biobetter therapies in major protein classes erythropoietin's, G-CSF, interferon-a, interferon-beta, insulin and insulin analogs, mAbs and TNF-a.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global biobetter therapeutics market, including companies such as Celgene, Amgen, Bristol-Myers Squibb, Amylin and Dainippon Sumitomo Pharma.
- Key M&A activities and licensing and co-development agreements that took place from 2010-2012 in the global Biobetters market.

Reasons to Get this Report

- Align your product portfolio to the markets with high growth potential.
- Develop business strategies by understanding the trends shaping and driving technological advancements in the field of biobetter therapies.
- Identify key molecules in development being used for biobetter therapies.
- Reinforce R&D pipelines by identifying common drug class biobetters in the pipeline for top selling protein classes.

Companies Mentioned in this Report: Amgen, Merck, Roche, Novo Nordisk, Sanofi-Aventis

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Biotechnology research reports at Fast Market Research

You may also be interested in these related reports:

- The Canadian Mining Sector - Market Opportunity and Entry Strategies, Analyses and Forecasts to 2015
- The Indian Mining Sector - Market Opportunity and Entry Strategies, Analyses and Forecasts to 2015
- Non-Life Insurance in India, Key Trends and Opportunities to 2015
- The Australian Packaging Industry - Market Opportunities and Entry Strategies, Analyses and Forecasts to 2015
- The Brazilian Mining Sector - Market Opportunity and Entry Strategies, Analyses and Forecasts to 2015
- The New Zealand Packaging Industry - Market Opportunities and Entry Strategies, Analyses and Forecasts to 2015
- The Canadian Packaging Industry - Market Opportunities and Entry Strategies, Analyses and Forecasts to 2015
- The Mexican Packaging Industry - Market Opportunities and Entry Strategies, Analyses and Forecasts to 2015
- Cell Therapeutics, Inc. (CTIC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile